Gravitational chiral anomaly and anomalous transport for fields with spin 3/2

In a fluid with vorticity and acceleration, an axial current arises in the third order of gradient expansion, called the kinematical vortical effect (KVE). While existing in the absence of gravitational fields, it is nevertheless associated with effects in curved space-time, namely with the gravitational chiral quantum anomaly. In this paper, the KVE transport coefficients were found using the Zubarev quantum-statistical density operator for the Rarita-Schwinger-Adler theory, which includes fields with spins 3/2 and 1/2. A prediction is made about the possible form of the transport coefficients for massless fields with arbitrary spin.Comment: 10 page

Novel phase transition at the Unruh temperature

In recent years, the theory of quantum phase transitions has rapidly developed. These are transitions at a zero temperature which are associated with a change of the theory parameters like couplings. In contrast, the classical phase transitions occur ``within'' the same theory (in particular, with the same couplings) and are associated with a change in temperature. Within the framework of a simple model of Dirac fields in the Euclidean Rindler space, we establish an intermediate case when the phase transition occurs at a finite temperature, but the temperature itself is of a quantum origin (the Unruh temperature). Moreover, the phase transition point is uniquely associated with the behavior of individual levels, namely at the Unruh temperature the two lowest Matsubara modes become singular on the Rindler horizon. This provides a new manifestation of the duality between the thermodynamic description and the geometric approach (the behavior of the quantum levels of particles living on a nontrivial geometric manifold). Although the considered example refers to the physics of black holes, we note the formal similarity of the Unruh temperature with the parameter characterizing quantum transitions in the theory of condensed matter.Comment: 11 pages, 2 figure

The Evolution of Compact Binary Star Systems

We review the formation and evolution of compact binary stars consisting of white dwarfs (WDs), neutron stars (NSs), and black holes (BHs). Binary NSs and BHs are thought to be the primary astrophysical sources of gravitational waves (GWs) within the frequency band of ground-based detectors, while compact binaries of WDs are important sources of GWs at lower frequencies to be covered by space interferometers (LISA). Major uncertainties in the current understanding of properties of NSs and BHs most relevant to the GW studies are discussed, including the treatment of the natal kicks which compact stellar remnants acquire during the core collapse of massive stars and the common envelope phase of binary evolution. We discuss the coalescence rates of binary NSs and BHs and prospects for their detections, the formation and evolution of binary WDs and their observational manifestations. Special attention is given to AM CVn-stars -- compact binaries in which the Roche lobe is filled by another WD or a low-mass partially degenerate helium-star, as these stars are thought to be the best LISA verification binary GW sources.Comment: 105 pages, 18 figure

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Tunable optical properties of transition metal dichalcogenide nanoparticles synthesized by femtosecond laser ablation and fragmentation

International audienceManipulation of resonant dielectric nanostructures is of paramount importance for next-generation photonic devices. Traditionally, researchers use two-dimensional or phase-change materials for this purpose. However, the former leads to small efficiency, while the latter lacks continuous changes. Here, we provide an alternative approach through laser-induced modification. Specifically, via a laser ablation process we synthesized molybdenum disulfide (MoS 2) nanoparticles (NPs), the composition of which we then controlled through laser fragmentation. It causes a transformation of MoS 2 into its oxide MoO 3Àx , which, in turn, results in pronounced modification of the optical response, owing to a large difference between their optical constants. In addition, laser-fragmented NPs have a several times larger photothermal response, compared to the original MoS 2 and classical silicon NPs. Thus, our MoS 2-based laser-tunable NPs open up a new perspective for resonant nanophotonics, in particular, photothermal therapy

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)